Overview
Pneumonic plague, caused by the bacterium Yersinia pestis infecting the lungs, is a rapidly progressing and highly lethal form of plague with mortality rates approaching 60% with prompt treatment and nearly 100% if treatment is delayed beyond 24 hours 1. This airborne transmission route makes it particularly dangerous, as it can lead to rapid outbreaks and pandemics. Historically significant for its devastating impact, pneumonic plague remains a concern due to potential bioterrorism threats and the emergence of multidrug-resistant strains 14. Given its high fatality rate and potential for rapid spread, early recognition and immediate intervention are critical in day-to-day clinical practice to prevent catastrophic outcomes 1.Pathophysiology
The pathophysiology of pneumonic plague involves the inhalation of Y. pestis bacilli, which rapidly disseminate via the respiratory tract and lymphatic system. Once inhaled, the bacteria are engulfed by alveolar macrophages, where they inhibit phagosome-lysosome fusion, preventing their destruction and facilitating their proliferation 1. The bacteria then release virulence factors such as LcrV and Yops (Yersinia outer proteins) through the type III secretion system, which interfere with host immune responses. This interference suppresses inflammatory cytokine production and disrupts neutrophil function, allowing the bacteria to spread to regional lymph nodes and beyond, leading to systemic infection 12. At the molecular level, CD4+ and CD8+ T cells play crucial roles in mounting an effective immune response, characterized by the production of IFN-γ, TNF-α, and IL-17A, which are essential for controlling the infection 116. Additionally, the activation of lung-resident memory T cells (TRM cells) has been shown to provide comprehensive protection against pneumonic plague, highlighting the importance of mucosal immunity in preventing severe disease 116.Epidemiology
Pneumonic plague is relatively rare but has significant regional outbreaks, particularly in parts of Africa, Asia, and the Americas where plague is endemic 14. Incidence figures are not consistently reported globally, but annual cases are typically in the thousands rather than millions 1. The disease predominantly affects adults, with no clear sex predilection, though certain occupational groups (e.g., farmers, veterinarians) and individuals living in or traveling to endemic areas are at higher risk 1. Environmental changes, including shifts in climate and habitat alterations, have been linked to recent outbreaks, underscoring the need for vigilance in changing ecological contexts 12. Trends suggest sporadic outbreaks rather than sustained epidemics, but the potential for rapid spread in crowded or immunocompromised populations remains a serious concern 1.Clinical Presentation
The clinical presentation of pneumonic plague often begins with nonspecific symptoms such as fever, chills, headache, and malaise, progressing rapidly to more specific respiratory symptoms like cough, dyspnea, and hemoptysis 1. Early signs may include pleuritic chest pain and hypoxemia, reflecting the acute pneumonic involvement. Atypical presentations can include confusion, delirium, and septic shock, especially in severe cases 1. Red-flag features include high fever, rapid progression of symptoms, and signs of systemic infection such as hypotension and disseminated intravascular coagulation (DIC). Prompt recognition of these features is crucial for timely intervention 1.Diagnosis
Diagnosis of pneumonic plague involves a combination of clinical suspicion, laboratory testing, and imaging. The diagnostic approach typically includes:Differential Diagnosis:
Management
First-Line Treatment
Second-Line Treatment
Specialist Escalation
Complications
Prognosis & Follow-Up
The prognosis for pneumonic plague is heavily dependent on the timeliness of diagnosis and initiation of appropriate treatment. Early intervention significantly improves survival rates, while delays can be fatal 1. Prognostic indicators include rapid clinical deterioration, presence of septic shock, and disseminated infection. Recommended follow-up includes:Special Populations
Key Recommendations
References
1 Singh AK, Majumder S, Wang X, Song R, Sun W. Lung Resident Memory T Cells Activated by Oral Vaccination Afford Comprehensive Protection against Pneumonic Yersinia pestis Infection. Journal of immunology (Baltimore, Md. : 1950) 2023. link 2 Lv M, Wang R, Wang X, Hu L, Zhang L, Wu C et al.. Pulmonary delivery of a humanized heavy-chain antibody LcrV-X19-R1 confers complete protection against fatal pneumonic plague in mice. International journal of biological macromolecules 2026. link 3 Sha J, Rosenzweig JA, Kirtley ML, van Lier CJ, Fitts EC, Kozlova EV et al.. A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague. Microbial pathogenesis 2013. link 4 Murphy GL, Whitworth LC. Construction of isogenic mutants of Pasteurella haemolytica by allelic replacement. Gene 1994. link90241-0) 5 Clarke CR, Short CR, Corstvet RE, Nobles D. Interaction between Pasteurella haemolytica, sulfadiazine/trimethoprim, and bovine viral diarrhea virus. American journal of veterinary research 1989. link